-
公开(公告)号：US5726044A
公开(公告)日：1998-03-10
申请号：US528122
申请日：1995-09-14
Applicant: Kin-Ming Lo , Yukio Sudo , Stephen D. Gillies
Inventor： Kin-Ming Lo , Yukio Sudo , Stephen D. Gillies
IPC: C12N15/09 , C07K14/16 , C07K14/475 , C07K14/55 , C07K14/705 , C07K14/71 , C07K16/00 , C07K16/28 , C12N5/10 , C12N15/62 , C12N15/85 , C12P21/02 , C07K16/46 , C12N15/11 , C12N15/13
CPC classification number: C07K14/005 , C07K14/475 , C07K14/55 , C07K14/705 , C07K14/71 , C07K16/00 , C07K16/28 , C12N15/62 , C12N15/625 , C12N15/85 , C07K2319/00 , C07K2319/02 , C07K2319/10 , C07K2319/30 , C07K2319/32 , C07K2319/35 , C07K2319/40 , C07K2319/50 , C07K2319/75 , C12N2740/16122 , C12N2740/16322
Abstract: Disclosed are DNAs produced by recombinant techniques for inducing the expression and subsequent secretion of a target protein. The DNAs encode, in their 5' to 3' direction, a secretion cassette, including a signal sequence and an immunoglobulin Fc region, and a target protein. The DNAs can be transfected into a host cell for the expression, production and subsequent secretion of the target protein as a fusion protein. The secreted protein can be collected from the extracellular space, and further purified as desired. The secreted fusion protein additionally can be proteolytically cleaved to release the target protein from the secretion cassette.
-
公开(公告)号：US5541087A
公开(公告)日：1996-07-30
申请号：US305700
申请日：1994-09-14
Applicant: Kin-Ming Lo , Yukio Sudo , Stephen D. Gillies
Inventor： Kin-Ming Lo , Yukio Sudo , Stephen D. Gillies
IPC: C12N15/09 , C07K14/16 , C07K14/475 , C07K14/55 , C07K14/705 , C07K14/71 , C07K16/00 , C07K16/28 , C12N5/10 , C12N15/62 , C12N15/85 , C12P21/02 , C07K16/46 , C12N15/11 , C12N15/13
CPC classification number: C07K14/005 , C07K14/475 , C07K14/55 , C07K14/705 , C07K14/71 , C07K16/00 , C07K16/28 , C12N15/62 , C12N15/625 , C12N15/85 , C07K2319/00 , C07K2319/02 , C07K2319/10 , C07K2319/30 , C07K2319/32 , C07K2319/35 , C07K2319/40 , C07K2319/50 , C07K2319/75 , C12N2740/16122 , C12N2740/16322
Abstract: Disclosed are DNAs produced by recombinant techniques for inducing the expression and subsequent secretion of a target protein. The DNAs encode, in their 5' to 3' direction, a secretion cassette, including a signal sequence and an immunoglobulin Fc region, and a target protein. The DNAs can be transfected into a host cell for the expression, production and subsequent secretion of the target protein as a fusion protein. The secreted protein can be collected from the extracellular space, and further purified as desired. The secreted fusion protein additionally can be proteolytically cleaved to release the target protein from the secretion cassette.
Abstract translation: 公开了通过重组技术产生的用于诱导靶蛋白的表达和随后分泌的DNA。 DNA在5'至3'方向编码分泌盒，包括信号序列和免疫球蛋白Fc区，以及靶蛋白。 DNA可以被转染到宿主细胞中，作为融合蛋白的靶蛋白的表达，产生和随后的分泌。 分泌的蛋白质可以从细胞外空间收集，并根据需要进一步纯化。 分泌的融合蛋白另外可以被蛋白水解切割以从分泌盒中释放靶蛋白。
-
公开(公告)号：US08470991B2
公开(公告)日：2013-06-25
申请号：US12768678
申请日：2010-04-27
Applicant: Stephen D. Gillies , Kin-Ming Lo , Susan Xiuqi Qian
Inventor： Stephen D. Gillies , Kin-Ming Lo , Susan Xiuqi Qian
CPC classification number: C07K16/3084 , A61K48/00 , C07K16/30 , C07K16/467 , C07K2317/24 , C07K2317/732
Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.
Abstract translation: 本发明提供了一种特异性结合人细胞表面鞘糖脂GD2的抗体家族。 抗体包含修饰的可变区，更特别地，修饰的框架区，当施用于人时，其降低其免疫原性。 抗体可以与治疗剂偶联并用于治疗癌症。
-
公开(公告)号：US20110038877A1
公开(公告)日：2011-02-17
申请号：US12834546
申请日：2010-07-12
Applicant: Jeffrey Way , Stephen D. Gillies , Kin-Ming Lo , Yuan Liu
Inventor： Jeffrey Way , Stephen D. Gillies , Kin-Ming Lo , Yuan Liu
CPC classification number: C07K14/5412 , A61K2039/505 , C07K14/7155 , C07K16/248 , C07K16/2866 , C07K16/3023 , C07K16/3053 , C07K16/3061 , C07K2317/24 , C07K2317/32 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/30
Abstract: The present invention provides an isolated IL-6 antagonist including an antibody variable region that prevents IL-6 from binding to gp130. The present invention also provides compositions and methods for treating IL-6 related diseases based on the IL-6 antagonists of the invention.
Abstract translation: 本发明提供了分离的IL-6拮抗剂，其包括防止IL-6与gp130结合的抗体可变区。 本发明还提供了基于本发明的IL-6拮抗剂治疗IL-6相关疾病的组合物和方法。
-
公开(公告)号：US20090098609A1
公开(公告)日：2009-04-16
申请号：US12325599
申请日：2008-12-01
Applicant: Stephen D. Gillies , Pascal A. Stein , Kin-Ming Lo
Inventor： Stephen D. Gillies , Pascal A. Stein , Kin-Ming Lo
CPC classification number: C07K14/55 , C07K2319/00
Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
Abstract translation: 本发明提供具有增加的治疗指数的细胞因子融合蛋白，以及增加这种融合蛋白的治疗指数的方法。 本发明的融合蛋白能够结合在细胞上表达的多于一种类型的细胞因子受体，并且还结合多种细胞类型。 此外，本发明的融合蛋白在患者体内表现出比相应的天然存在的细胞因子更长的循环半衰期。
-
Patent Agency Ranking
公开(公告)号：US07169904B2
公开(公告)日：2007-01-30
申请号：US10737208
申请日：2003-12-16
Applicant: Stephen D. Gillies , Kin-Ming Lo , Susan X. Qian
Inventor： Stephen D. Gillies , Kin-Ming Lo , Susan X. Qian
IPC: C07K16/00
CPC classification number: C07K16/3084 , A61K48/00 , C07K16/30 , C07K16/467 , C07K2317/24 , C07K2317/732
Abstract: The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies may be coupled to a therapeutic agent and used in the treatment of cancer.
-
公开(公告)号：US07091321B2
公开(公告)日：2006-08-15
申请号：US09780668
申请日：2001-02-09
Applicant: Stephen D. Gillies , Christa Burger , Kin-Ming Lo
Inventor： Stephen D. Gillies , Christa Burger , Kin-Ming Lo
IPC: A61K39/395 , C07K16/00
CPC classification number: C07K5/1013 , A61K47/6813 , A61K47/6851 , A61K2039/505 , C07K14/525 , C07K14/55 , C07K16/00 , C07K16/30 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/73 , C07K2319/00
Abstract: Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the junction region between the antibody moiety and the fused protein moiety in an antibody-based fusion protein. An antibody-based fusion protein with an altered amino acid sequence in the junction region has a greater circulating half-life when administered to a mammal. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.
-
公开(公告)号：US20130165634A1
公开(公告)日：2013-06-27
申请号：US13533250
申请日：2012-06-26
Applicant: Kin-Ming Lo , Yue Li , Stephen D. Gillies
Inventor： Kin-Ming Lo , Yue Li , Stephen D. Gillies
IPC: C07K14/78
CPC classification number: A61K38/00 , C07K14/515 , C07K14/78 , C07K2317/24 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/75 , C12N9/6435 , C12N15/62 , C12Y304/21007 , Y10S530/81
Abstract: A fusion protein of the invention comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein comprises a collagen XVIII fragment, preferably endostatin. The immunoglobulin Fc region preferably comprises a hinge region, a CH2 region, and a CH3 region.
Abstract translation: 本发明的融合蛋白包含免疫球蛋白Fc区和与免疫球蛋白Fc区连接的第一靶蛋白。 第一靶蛋白包含胶原XVIII片段，优选内皮抑素。 免疫球蛋白Fc区优选包含铰链区，CH2区和CH3区。
-
公开(公告)号：US08066994B2
公开(公告)日：2011-11-29
申请号：US11489653
申请日：2006-07-19
Applicant: Stephen D. Gillies , Jeffrey Way , Kin-Ming Lo
Inventor： Stephen D. Gillies , Jeffrey Way , Kin-Ming Lo
CPC classification number: C07K16/30 , C07K2317/52 , C07K2317/53 , C07K2319/00 , C07K2319/30
Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.
Abstract translation: 公开了用于有效表达抗体融合蛋白的方法和组合物。 本发明的抗体融合蛋白包括含有多于一种类型的抗体和/或突变体抗体序列的序列的杂交抗体部分。 本发明的混合抗体融合蛋白可以以高水平产生，并且可以组合不同抗体类型的功能特征以及非抗体部分的功能性质。
-
公开(公告)号：US08043608B2
公开(公告)日：2011-10-25
申请号：US12411388
申请日：2009-03-25
Applicant: Stephen D. Gillies , Kin-Ming Lo , John S. Wesolowski, Jr.
Inventor： Stephen D. Gillies , Kin-Ming Lo , John S. Wesolowski, Jr.
CPC classification number: C07K14/005 , A61K39/12 , A61K39/21 , A61K39/385 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55522 , A61K2039/55533 , A61K2039/55566 , A61K2039/6056 , C07K14/475 , C07K14/52 , C07K14/535 , C07K14/705 , C07K19/00 , C07K2319/00 , C07K2319/02 , C07K2319/40 , C07K2319/75 , C12N15/62 , C12N2740/16122 , C12N2740/16134 , Y10S930/141
Abstract: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.
Abstract translation: 本文公开了用于增强哺乳动物中预选的蛋白质或肽抗原的免疫原性的方法和组合物。 通过将预选抗原融合到免疫球蛋白重链恒定区以产生Fc-抗原融合蛋白来增强免疫原性。 Fc抗原融合蛋白结合抗原呈递细胞表面上的Fc受体，从而将抗原靶向哺乳动物中的抗原呈递细胞。 此外，所公开的是一类佐剂，例如Fc-佐剂融合蛋白，其与Fc-抗原融合蛋白组合使用以增强或调节针对预选抗原的特定免疫应答。
-
-
-
-
-
-
-
-
-
Search Results
67
records
(took 0.038 seconds)
